
|Videos|April 13, 2017
FDA Approval Sought in Multiple Myeloma, 2017 AACR Annual Meeting Highlights, and More
Advertisement
Episodes in this series

Now Playing
Patrick Borgen, MD, discusses an FDA approval sought for an agent in multiple myeloma, impressive phase III findings in non—small cell lung cancer, a change in USPSTF recommendations for PSA screening, and highlights from the 2017 AACR Annual Meeting.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
2
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
3
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
4
Bispecific-Based Approaches Highlight Key Multiple Myeloma Data Set to Emerge at EHA 2026
5





























































